Table 1 Clinical features of patients with HIV-associated Burkitt lymphoma at diagnosis (n = 41)
Features | N (%) |
|---|---|
Sex | |
Male | 36 (87.8) |
Female | 5 (12.2) |
Age | |
<40 | 20 (48.8) |
≥40 | 21 (51.2) |
Household registration | |
Rural | 13 (31.7) |
Urban | 28 (68.3) |
Marital state | |
Single | 15 (36.6) |
Being married | 24 (58.5) |
Divorced/widowed | 2 (4.9) |
Primary site | |
Nodal | 31 (75.6) |
Extra-nodal | 10 (24.4) |
Ann Arbor stage | |
I-II | 10 (24.4) |
III-IV | 31 (75.6) |
B symptom | |
Presence | 26 (63.4) |
Absence | 15 (36.6) |
ECOG PS | |
0–1 | 25 (61.0) |
≥2 | 16 (39.0) |
BM involvement | |
Yes | 19 (46.3) |
No | 22 (53.7) |
CNS involvement | |
Yes | 8 (19.5) |
No | 33 (80.5) |
Bulky disease | |
Yes | 14 (34.1) |
No | 27 (65.9) |
CD4 count | |
≤100cells/μl | 5 (12.2) |
>100cells/μl | 36 (87.8) |
LDH level | |
≤ 3x ULN | 21 (51.2) |
>3x ULN | 20 (48.8) |
Other viral infections | |
Epstein-Barr virus | 16(39.0) |
Hepatitis B | 3(7.3) |
Hepatitis C | 0(0) |
BL-IPI staging | |
Low | 7 (17.1) |
Intermediate | 22 (53.7) |
High | 12 (29.2) |
First-line treatment | |
R-Hyper-CVAD/MA | 12 (29.3) |
R-DA-EPOCH | 12 (29.3) |
DA-EPOCH | 10 (24.3) |
Others | 7 (17.1) |
Rituximab | |
With | 24 (58.5) |
Without | 17 (41.5) |